Skip to main content
Premium Trial:

Request an Annual Quote

Great Basin Scientific Prices $2.7M Securities Offering

NEW YORK (GenomeWeb) – Great Basin Scientific said today that it has priced $2.7 million of securities units for sale through a registered public offering.

The offering will consist of 8.9 million units comprising Class A Units and Class B Units priced at $.30 and $.29, respectively. Each Class A unit will consist of one share of Great Basin's common stock and one Series J warrant to purchase 2.5 shares of the firm's common stock at $.30 apiece. Each Class B unit will consist of one prefunded Series K warrant to purchase one share of common stock at $.30 and one Series J warrant.

Class B units are being offered to any purchaser whose purchase of Class A units would result in that purchaser owning more than 4.99 percent or 9.99 percent, at the purchaser's election, of Great Basin's issued and outstanding common stock following consummation of the offering, the firm said.

Roth Capital Partners acted as the exclusive placement agent for the offering. Great Basin said that it will use the expected $2 million in net proceeds from the sale for research and development, sales and marketing, the redemption of certain notes, and for general corporate purposes including working capital.

Last month, Great Basin said that it had expected to gross $3.5 million through a unit offering.

During midday trading on the Nasdaq, shares of Great Basin were down nearly 21 percent to $.31.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.